You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK):核心產品CS5001(ROR1ADC)的首次人體研究最新數據在2024年ASCO會議上發佈
格隆匯 06-04 08:05

格隆匯6月4日丨基石藥業-B(02616.HK)發佈公吿,公司研發管線2.0的重磅產品CS5001 (ROR1 ADC)治療晚期實體瘤和淋巴瘤患者的1a/1b期全球多中心首次人體研究的數據在美國臨牀腫瘤學會(ASCO)年會上以壁報形式公佈。

基石藥業首席執行官、研發總裁兼執行董事楊建新博士表示:“我們非常高興能在ASCO這一著名會議上公佈CS5001的首次人體研究數據。CS5001分子設計的的獨特性已被其在臨牀上所展現出的良好耐受性和安全性充分印證。雖然研究仍處於劑量探索階段,我們已經可以在多種惡性腫瘤中觀察到CS5001明顯的抗腫瘤活性,包括瀰漫大B細胞淋巴瘤(DLBCL)、霍奇金淋巴瘤、胰腺癌、非小細胞肺癌(NSCLC)、乳腺癌,卵巢癌等。值得強調的是,CS5001是目前已知首個針對實體瘤展現出臨牀抗腫瘤活性的ROR1 ADC。令我們更為欣喜的是,隨着研究穩步推進,在ASCO壁報數據截止日之後,我們在血液瘤和實體瘤中持續收穫了更多CS5001抗腫瘤活性的臨牀證據。這些更新的臨牀數據將在後續的投資者會議或學術大會上公佈,我們也期待進一步挖掘CS5001這款潛在同類最佳ROR1 ADC在廣泛瘤種中的開發潛力。”

CS5001是一種新型ROR1導向的ADC,具有吡咯並苯二氮卓(PBD)前藥的獨特設計。首次人體研究旨在評估CS5001在晚期實體瘤和B細胞淋巴瘤患者中的安全性、藥代動力學(PK)特徵和抗腫瘤活性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account